Carvolix
Paris · Founded 2011
About Carvolix
Affluent Medical develops innovative new-generation mini-invasive implants to restore essential physiological functions in these areas: - Kardiozis aims to prevent endoleaks and risks of recurrence of the abdominal aortic aneurysm allowing patients to live more serenely facing an unpredictable risk of breakage; - Kalios and Epygon aim to provide more physiological surgical treatments for the repair or replacement of the mitral valve of the heart. Kalios can treat residual post-operative leakage and recurrent mitral insufficiency without having to reoperate patients. Epygon is today the only developing transcatheter valve to restore natural blood flow and safeguard the left ventricle. - Finally, Artus is the first electronically activatable artificial sphincter to treat stress urinary incontinence in men and women.
Company Facts
- Founded: 2011
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $22.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2024)
- Ticker: epa:AFME
- Website: https://www.affluentmedical.com/
- Phone: +33 1 44 54 36 66
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/carvolix-55180 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.